Palisade Bio Inc
NASDAQ:PALI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Palisade Bio Inc
Cash Interest Paid
Palisade Bio Inc
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Palisade Bio Inc
NASDAQ:PALI
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Interest Paid
$3.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Interest Paid
$2.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash Interest Paid
$2.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Interest Paid
$1.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Interest Paid
$633m
|
CAGR 3-Years
25%
|
CAGR 5-Years
13%
|
CAGR 10-Years
17%
|
|
Palisade Bio Inc
Glance View
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 13 full-time employees. The company went IPO on 2006-12-20. The firm is focused on discovering, developing, and commercializing oral therapies that target diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the digestive enzyme inhibitor, tranexamic acid, intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from, among other things, reduced blood flow to the intestine, infections, or due to surgery. Its LB1148 has been advanced to Phase III clinical trials for the return of bowel function indication, which is a protease inhibitor that helps to restore bowel function and reduce abdominal adhesions following surgery.
